Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | CHAT | P28329 | 1/20 | 0.57 |
| ▸ | APP | P05067 | 4/20 | 0.54 |
| ▸ | CYP1A1 | P04798 | 5/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.54 |
| ▸ | CYP1B1 | Q16678 | 5/20 | 0.54 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.53 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.52 |
| ▸ | BACE1 | P56817 | 1/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.50 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2604932 | 0.90 | LMNA (0.77) | LMNAMAPTCHATCYP1A1CYP1A2 | |
| SCHEMBL2604952 | 0.88 | MAPT (0.79) | LMNAMAPTCHATAPPCYP1A1 | |
| SCHEMBL11670549 | 0.81 | MAPT (0.60) | LMNAMAPTCHATABCB1BACE1 | |
| SCHEMBL11671491 | 0.81 | MAPT (0.60) | LMNAMAPTCHATABCB1BACE1 | |
| SCHEMBL2604937 | 0.81 | MAPT (1.00) | LMNAMAPTCHATCYP1A1CYP1A2 | |
| SCHEMBL7915398 | 0.80 | MAPT (0.63) | LMNAMAPTCHATCYP1A1CYP1A2 | |
| SCHEMBL7915395 | 0.80 | MAPT (0.63) | LMNAMAPTCHATCYP1A1CYP1A2 | |
| SCHEMBL12611159 | 0.80 | LMNA (0.59) | LMNAMAPTCHATCYP1A1CYP1A2 | |
| SCHEMBL11819366 | 0.79 | MAPT (0.61) | LMNAMAPTCHATABCB1BACE1 | |
| SCHEMBL11821979 | 0.79 | MAPT (0.61) | LMNAMAPTCHATABCB1BACE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158380-B2 | Imaging agents for protein misfolding | NEW YORK UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-8158380-B2 | Imaging agents for protein misfolding | NEW YORK UNIVERSITY (US) | 2012-04-17 | — | — | US | disclosed |
| US-20100279340-A1 | Imaging agents for protein misfolding | NYU (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100279340-A1 | Imaging agents for protein misfolding | NYU (US) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279340-A1 | Imaging agents for protein misfolding | APBA1, APP, SPG11 | LMNA 1999/4885MAPT 4/4885CHAT 3608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.